Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 299Thoracic 36Genitourinary 32Gynecologic 24Dermatologic 21Head & Neck 15Sarcoma 13Breast 13CNS 10Endocrine 7Other solid neoplasm 6Lymphoid 5Plasma cell 4NET 3Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 423Precursor Cell Lymphoblastic Leukemia-Lymphoma 222Hematologic Neoplasms 212Leukemia, Lymphocytic, Chronic, B-Cell 184Myelodysplastic Syndromes 153Leukemia 121Lymphoma 86Lymphoma, Non-Hodgkin 76Multiple Myeloma 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Recurrence 59Leukemia, Myelomonocytic, Chronic 53Neoplasms 51Leukemia, Biphenotypic, Acute 46Burkitt Lymphoma 44Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 42Myeloproliferative Disorders 41Lymphoma, Mantle-Cell 39Lymphoma, Large B-Cell, Diffuse 38Hodgkin Disease 35Lymphoma, Follicular 32Lymphoma, B-Cell 30Waldenstrom Macroglobulinemia 25Lymphoma, B-Cell, Marginal Zone 25Leukemia, B-Cell 25Anemia, Refractory, with Excess of Blasts 21Primary Myelofibrosis 20Hematologic Diseases 20Leukemia, Myeloid, Chronic-Phase 19Myelodysplastic-Myeloproliferative Diseases 18

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Other hematologic neoplasm × 90 days × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06971848 2026-03-30

ETCABIO

University Hospital, Angers

Phase NA Not yet recruiting
70 enrolled
GastrointestinalLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellThoracic

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡